Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2)
- HEPATOCELLULAR REDISTRIBUTION OF MULTIDRUG RESISTANT PROTEIN (MRP2): A COMPENSATORY MECHANISM IN ANTIDEPRESSANT INDUCED CHOLESTASIS. Milkiewicz, P.; Chilton, A.; Hubscher, S.G.; Elias, E. // Gut;Apr2003 Supplement 1, Vol. 52, pA105
Background: Antidepressive drugs such as tricyclic antidepressants and monoamine-oxidase inhibitors may occasionally induce prolonged or even fatal jaundice. The mechanisms by which the liver responds to antidepressive drug induced cholestasis are unknown. Patients: We report two cases of...
- Cholestasis in patients with acquired immunodeficiency... Liu, Katherine J.M.; Atten, Mary Jo // American Surgeon;Jun1997, Vol. 63 Issue 6, p519
Reviews cholestasis in patients with acquired immunodeficiency syndrome (AIDS). Underlying causes of cholestasis; Predominant findings in patients with AIDS and hepatocellular diseases; Acalculous cholecystitis described; Two disease entities of abnormalities of intraheptic/extraheptic duct.
- Everolimus. // Reactions Weekly;6/19/2010, Issue 1306, p23
The article describes the cases of two patients who developed cholestasis after receiving everolimus.
- Corrigendum. // Journal of Clinical Investigation;Jul2004, Vol. 114 Issue 1, p142
Presents a correction to the article "Cathepsin B Inactivation Attenuates Hepatic Injury and Fibrosis During Cholestasis" that was previously published in the vol. 112, 2003 issue of the "Journal of Clinical Investigation."
- Determining when to change to a different antidepressant. Huffman, Grace Brooke // American Family Physician;2/15/1997, Vol. 55 Issue 3, p947
Focuses on a study by F.M. Quitkin, et al, published in the `Archives of General Psychiatry,' which tries to determine when patients should be considered unresponsive to antidepressant therapy and should have their treatment changed. `Chronological milestones to guide drug change. When should...
- New antidepressant drugs called major treatment advances. // Executive Health's Good Health Report;Oct93, Vol. 30 Issue 1, p3
Reports on the acknowledgement of antidepressant drugs Zoloft and Paxil as improvements over previously available antidepressants. Selective serotonin reuptake inhibitors; Effectiveness in treating obsessive compulsive disorders, hypochondriasis and anorexia nervosa; Testing on impulsive behavior.
- Focus on mirtazapine: A new antidepressant with noradrenergic and specific serotonergic activity. Kehoe, William A.; Schorr, Robert B. // Formulary;Jun96, Vol. 31 Issue 6, p455
Focuses on the antidepressant mirtazapine. Chemistry and pharmacology; Serotonic receptors and possible therapeutic applications; Pharmacokinetics; Clinical trials; Adverse effects; Drug interactions; Formulary considerations; Dose and administration. INSET: Formulary considerations..
- The power of Prozac. Rust, Michael // Insight on the News;09/14/98, Vol. 14 Issue 34, p16
Presents information on the antidepressant Prozac. Annual cost of antidepressants in the United States as a result of early death, lost workdays and lowered productivity; Details on Prozac; Investigations being conducted by the Food and Drug Administration on the effort of antidepressants and...
- Half of antidepressants' benefit attributed to placebo effect. // Executive Health's Good Health Report;Nov96, Vol. 33 Issue 2, p8
Reports that 50 percent of an antidepressant medication's effect can be attributed to the placebo response according to a study made by Doctor Guy Sapirstein from the University of Connecticut. Result of 25 ears' analysis of 3,250 patients with depression.